Integrating machine learning into the in silico clinical trial pipeline

Area of Science:

• Computational biology
• Biomedical informatics
• Clinical trial methodology

Background:

• Traditional clinical trials are resource-intensive and assess average effects, limiting personalized treatment exploration.
• In silico trials offer cost-effectiveness and design flexibility, analyzing treatment response heterogeneity.
• Mechanistic mathematical models, calibrated with clinical data, underpin current in silico trial approaches.

Purpose of the Study:

• To explore the integration of machine learning (ML) into in silico clinical trials.
• To identify opportunities and challenges of using ML across various stages of in silico trials.
• To enhance the feasibility, interpretability, and reliability of in silico trial methodologies.

Main Methods:

• Review of current in silico trial methodologies and their reliance on mechanistic models.
• Discussion of potential applications of machine learning (ML) tools in in silico trial design and analysis.
• Consideration of expert modeler's role in applying ML for enhanced trial outcomes.

Main Results:

• ML offers significant potential to improve in silico trial accuracy and informativeness.
• ML can aid in biomarker identification and interpretation of trial results.
• Thoughtful ML application can enhance the reliability and feasibility of in silico trials.

Conclusions:

• Machine learning can significantly augment in silico clinical trials when applied by expert modelers.
• Enhanced in silico trials have the potential to accelerate drug development pipelines.
• ML-assisted in silico trials can facilitate the identification of optimal treatments for individual patients.